InVitria’s Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers and enhances diagnostic performance by improving specificity.
Fort Collins, CO, April 17, 2009 / b3c newswire / - Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA).
The advantages of Recombinant Albumin-DX include:
Reduce non-specific binding and improve specificity;
Improved consistency due to recombinant manufacturing;
Improved stabilization of sensitive proteins and biomarkers; and
Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
InVitria develops, manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture, biopharmaceutical formulation, stem cell & regenerative medicine, medical devices and diagnostics.